ID   PGFRA_HUMAN             Reviewed;        1089 AA.
AC   P16234; B2RE69; E9PBH0; Q6P4H5; Q96KZ7; Q9UD28;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Platelet-derived growth factor receptor alpha;
DE            Short=PDGF-R-alpha;
DE            Short=PDGFR-alpha;
DE            EC=2.7.10.1;
DE   AltName: Full=Alpha platelet-derived growth factor receptor;
DE   AltName: Full=Alpha-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member A;
DE   AltName: Full=CD140a antigen;
DE   AltName: Full=Platelet-derived growth factor alpha receptor;
DE   AltName: Full=Platelet-derived growth factor receptor 2;
DE            Short=PDGFR-2;
DE   AltName: CD_antigen=CD140a;
DE   Flags: Precursor;
GN   Name=PDGFRA; Synonyms=PDGFR2, RHEPDGFRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH PDGFA AND
RP   PDGFB.
RC   TISSUE=Foreskin;
RX   PubMed=2544881; DOI=10.1073/pnas.86.13.4917;
RA   Claesson-Welsh L., Eriksson A., Westermark B., Heldin C.H.;
RT   "cDNA cloning and expression of the human A-type platelet-derived
RT   growth factor (PDGF) receptor establishes structural similarity to the
RT   B-type PDGF receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4917-4921(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AUTOPHOSPHORYLATION, TISSUE
RP   SPECIFICITY, AND INTERACTION WITH PDGFA AND PDGFB.
RC   TISSUE=Brain;
RX   PubMed=2536956; DOI=10.1126/science.2536956;
RA   Matsui T., Heidaran M., Miki T., Popescu N., la Rochelle W., Kraus M.,
RA   Pierce J., Aaronson S.;
RT   "Isolation of a novel receptor cDNA establishes the existence of two
RT   PDGF receptor genes.";
RL   Science 243:800-804(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8586421; DOI=10.1006/geno.1995.9883;
RA   Kawagishi J., Ku T.;
RT   "Structure, organization, and transcription units of the human alpha-
RT   platelet-derived growth factor receptor gene, PDGFRA.";
RL   Genomics 30:224-232(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-478.
RC   TISSUE=Lung, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   PRO-478.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 579-1089, DISEASE, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY OF FIP1L1-PDGFRA FUSION PROTEIN.
RC   TISSUE=Eosinophil;
RX   PubMed=12808148; DOI=10.1073/pnas.0932698100;
RA   Griffin J.H., Leung J., Bruner R.J., Caligiuri M.A., Briesewitz R.;
RT   "Discovery of a fusion kinase in EOL-1 cells and idiopathic
RT   hypereosinophilic syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7830-7835(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 823-876, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A.,
RA   Srivastava S., Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [9]
RP   FUNCTION AS PDGFA AND PDGFB RECEPTOR IN CELL PROLIFERATION AND
RP   CHEMOTAXIS, AND SUBCELLULAR LOCATION.
RX   PubMed=2554309; DOI=10.1073/pnas.86.21.8314;
RA   Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S.,
RA   LaRochelle W.J., Ruggiero M., Aaronson S.A.;
RT   "Independent expression of human alpha or beta platelet-derived growth
RT   factor receptor cDNAs in a naive hematopoietic cell leads to
RT   functional coupling with mitogenic and chemotactic signaling
RT   pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989).
RN   [10]
RP   INTERACTION WITH PLCG1 AND SRC.
RX   PubMed=2173144; DOI=10.1126/science.2173144;
RA   Anderson D., Koch C.A., Grey L., Ellis C., Moran M.F., Pawson T.;
RT   "Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to
RT   activated growth factor receptors.";
RL   Science 250:979-982(1990).
RN   [11]
RP   INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR
RP   PDGFA AND PDGFB, AND AUTOPHOSPHORYLATION.
RX   PubMed=1709159;
RA   Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A.,
RA   Bowen-Pope D.F., Cooper J.A., Kazlauskas A.;
RT   "Platelet-derived growth factor (PDGF) stimulates PDGF receptor
RT   subunit dimerization and intersubunit trans-phosphorylation.";
RL   J. Biol. Chem. 266:8987-8992(1991).
RN   [12]
RP   FUNCTION AS PDGFB RECEPTOR IN CHEMOTAXIS; CELL PROLIFERATION;
RP   PHOSPHORYLATION OF PLCG1; ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE
RP   AND REGULATION OF PHOSPHATIDYLINOSITOL METABOLISM, INTERACTION WITH
RP   PIK3R, PHOSPHORYLATION AT TYR-731 AND TYR-742, AND MUTAGENESIS OF
RP   TYR-731 AND TYR-742.
RX   PubMed=1646396; DOI=10.1128/MCB.11.7.3780;
RA   Yu J.C., Heidaran M.A., Pierce J.H., Gutkind J.S., Lombardi D.,
RA   Ruggiero M., Aaronson S.A.;
RT   "Tyrosine mutations within the alpha platelet-derived growth factor
RT   receptor kinase insert domain abrogate receptor-associated
RT   phosphatidylinositol-3 kinase activity without affecting mitogenic or
RT   chemotactic signal transduction.";
RL   Mol. Cell. Biol. 11:3780-3785(1991).
RN   [13]
RP   INTERACTION WITH PDGFA AND PDGFB.
RX   PubMed=7679113;
RA   Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L.,
RA   LaRochelle W.J., Giese N.A.;
RT   "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB
RT   binding to alpha and beta PDGF receptor.";
RL   J. Biol. Chem. 268:3625-3631(1993).
RN   [14]
RP   FUNCTION AS PDGFA RECEPTOR IN REGULATION OF PLATELET ACTIVATION,
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8188664;
RA   Vassbotn F.S., Havnen O.K., Heldin C.H., Holmsen H.;
RT   "Negative feedback regulation of human platelets via autocrine
RT   activation of the platelet-derived growth factor alpha-receptor.";
RL   J. Biol. Chem. 269:13874-13879(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-988 AND TYR-1018, AND INTERACTION WITH PLCG1.
RX   PubMed=7535778; DOI=10.1074/jbc.270.13.7773;
RA   Eriksson A., Naanberg E., Roennstrand L., Engstroem U., Hellman U.,
RA   Rupp E., Carpenter G., Heldin C.H., Claesson-Welsh L.;
RT   "Demonstration of functionally different interactions between
RT   phospholipase C-gamma and the two types of platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 270:7773-7781(1995).
RN   [16]
RP   FUNCTION IN PROMOTING CHEMOTAXIS.
RX   PubMed=8760137;
RA   Osornio-Vargas A.R., Lindroos P.M., Coin P.G., Badgett A.,
RA   Hernandez-Rodriguez N.A., Bonner J.C.;
RT   "Maximal PDGF-induced lung fibroblast chemotaxis requires PDGF
RT   receptor-alpha.";
RL   Am. J. Physiol. 271:L93-L99(1996).
RN   [17]
RP   PHOSPHORYLATION AT TYR-768.
RX   PubMed=8617789; DOI=10.1074/jbc.271.9.5101;
RA   Yokote K., Mori S., Siegbahn A., Ronnstrand L., Wernstedt C.,
RA   Heldin C.H., Claesson-Welsh L.;
RT   "Structural determinants in the platelet-derived growth factor alpha-
RT   receptor implicated in modulation of chemotaxis.";
RL   J. Biol. Chem. 271:5101-5111(1996).
RN   [18]
RP   INTERACTION WITH GRB7 AND PIK3R1.
RX   PubMed=8940081; DOI=10.1074/jbc.271.48.30942;
RA   Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.;
RT   "Grb7 is a downstream signaling component of platelet-derived growth
RT   factor alpha- and beta-receptors.";
RL   J. Biol. Chem. 271:30942-30949(1996).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF PTPN11; ACTIVATION OF HRAS AND
RP   REGULATION OF CELL PROLIFERATION, PHOSPHORYLATION AT TYR-720,
RP   INTERACTION WITH GRB2; PTPN11; PLCG1 AND PIK3R1, AUTOPHOSPHORYLATION,
RP   AND MUTAGENESIS OF TYR-720.
RX   PubMed=8943348; DOI=10.1128/MCB.16.12.6926;
RA   Bazenet C.E., Gelderloos J.A., Kazlauskas A.;
RT   "Phosphorylation of tyrosine 720 in the platelet-derived growth factor
RT   alpha receptor is required for binding of Grb2 and SHP-2 but not for
RT   activation of Ras or cell proliferation.";
RL   Mol. Cell. Biol. 16:6926-6936(1996).
RN   [20]
RP   INTERACTION WITH CRK, PHOSPHORYLATION AT TYR-762, AND MUTAGENESIS OF
RP   TYR-762.
RX   PubMed=10733900; DOI=10.1006/bbrc.2000.2374;
RA   Matsumoto T., Yokote K., Take A., Takemoto M., Asaumi S.,
RA   Hashimoto Y., Matsuda M., Saito Y., Mori S.;
RT   "Differential interaction of CrkII adaptor protein with platelet-
RT   derived growth factor alpha- and beta-receptors is determined by its
RT   internal tyrosine phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 270:28-33(2000).
RN   [21]
RP   INTERACTION WITH SHF, AND PHOSPHORYLATION AT TYR-720.
RX   PubMed=11095946; DOI=10.1006/bbrc.2000.3847;
RA   Lindholm C.K., Frantz J.D., Shoelson S.E., Welsh M.;
RT   "Shf, a Shb-like adapter protein, is involved in PDGF-alpha-receptor
RT   regulation of apoptosis.";
RL   Biochem. Biophys. Res. Commun. 278:537-543(2000).
RN   [22]
RP   FUNCTION IN PLATELET ACTIVATION.
RX   PubMed=10947961; DOI=10.1042/bj3500469;
RA   Selheim F., Fukami M.H., Holmsen H., Vassbotn F.S.;
RT   "Platelet-derived-growth-factor-induced signalling in human platelets:
RT   phosphoinositide-3-kinase-dependent inhibition of platelet
RT   activation.";
RL   Biochem. J. 350:469-475(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF MAPK1/ERK2 AND/OR MAPK3/ERK1, DEGRADATION,
RP   PHOSPHORYLATION AT TYR-572 AND TYR-574, AND MUTAGENESIS OF TYR-572 AND
RP   TYR-574.
RX   PubMed=10734113; DOI=10.1074/jbc.275.13.9620;
RA   Rosenkranz S., Ikuno Y., Leong F.L., Klinghoffer R.A., Miyake S.,
RA   Band H., Kazlauskas A.;
RT   "Src family kinases negatively regulate platelet-derived growth factor
RT   alpha receptor-dependent signaling and disease progression.";
RL   J. Biol. Chem. 275:9620-9627(2000).
RN   [24]
RP   FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC.
RX   PubMed=11297552; DOI=10.1074/jbc.M101056200;
RA   Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O.,
RA   Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M.,
RA   Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.;
RT   "Platelet-derived growth factor C (PDGF-C), a novel growth factor that
RT   binds to PDGF alpha and beta receptor.";
RL   J. Biol. Chem. 276:27406-27414(2001).
RN   [25]
RP   SUBCELLULAR LOCATION, INTERACTION WITH SRC, AND MUTAGENESIS OF TYR-572
RP   AND TYR-574.
RX   PubMed=14644164; DOI=10.1016/j.yexcr.2003.08.001;
RA   Avrov K., Kazlauskas A.;
RT   "The role of c-Src in platelet-derived growth factor alpha receptor
RT   internalization.";
RL   Exp. Cell Res. 291:426-434(2003).
RN   [26]
RP   INVOLVEMENT IN HES.
RX   PubMed=12660384; DOI=10.1056/NEJMoa025217;
RA   Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D.,
RA   Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C.,
RA   Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M.,
RA   Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I.,
RA   Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G.;
RT   "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as
RT   a therapeutic target of imatinib in idiopathic hypereosinophilic
RT   syndrome.";
RL   N. Engl. J. Med. 348:1201-1214(2003).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1; MAP KINASES; STAT1 AND STAT3,
RP   INVOLVEMENT IN GIST, VARIANTS ASP-561; VAL-842; 842-ASP--HIS-845 DEL
RP   AND 845-HIS--PRO-448 DEL, AND CHARACTERIZATION OF VARIANTS ASP-561;
RP   VAL-842; 842-ASP--HIS-845 DEL AND 845-HIS--PRO-448 DEL.
RX   PubMed=12522257; DOI=10.1126/science.1079666;
RA   Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J.,
RA   Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D.,
RA   Fletcher C.D., Fletcher J.A.;
RT   "PDGFRA activating mutations in gastrointestinal stromal tumors.";
RL   Science 299:708-710(2003).
RN   [28]
RP   INVOLVEMENT IN GIST, VARIANTS ASP-561; LYS-659; TYR-842; VAL-842;
RP   842-ASP--HIS-845 DEL 845-HIS--PRO-448 DEL AND CYS-849,
RP   CHARACTERIZATION OF VARIANTS ASP-561; LYS-659; TYR-842; VAL-842;
RP   842-ASP--HIS-845 DEL 845-HIS--PRO-448 DEL AND CYS-849, AND ENZYME
RP   REGULATION.
RX   PubMed=15928335; DOI=10.1200/JCO.2005.14.068;
RA   Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L.,
RA   Harrell P., Shiraga S., Bainbridge T., Morich J., Heinrich M.C.;
RT   "PDGFRA mutations in gastrointestinal stromal tumors: frequency,
RT   spectrum and in vitro sensitivity to imatinib.";
RL   J. Clin. Oncol. 23:5357-5364(2005).
RN   [29]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=17141222; DOI=10.1016/j.febslet.2006.11.034;
RA   Vantler M., Huntgeburth M., Caglayan E., Ten Freyhaus H., Schnabel P.,
RA   Rosenkranz S.;
RT   "PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha
RT   receptor is negatively regulated by Src family kinases.";
RL   FEBS Lett. 580:6769-6776(2006).
RN   [30]
RP   PHOSPHORYLATION AT TYR-754.
RX   PubMed=17604334; DOI=10.1158/1535-7163.MCT-06-0720;
RA   Stock P., Monga D., Tan X., Micsenyi A., Loizos N., Monga S.P.;
RT   "Platelet-derived growth factor receptor-alpha: a novel therapeutic
RT   target in human hepatocellular cancer.";
RL   Mol. Cancer Ther. 6:1932-1941(2007).
RN   [31]
RP   INTERACTION WITH HHV-5 GB.
RX   PubMed=20660204; DOI=10.1128/JVI.00710-10;
RA   Feire A.L., Roy R.M., Manley K., Compton T.;
RT   "The glycoprotein B disintegrin-like domain binds beta 1 integrin to
RT   mediate cytomegalovirus entry.";
RL   J. Virol. 84:10026-10037(2010).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF STAT 5A AND/OR STAT5B, ROLE IN
RP   HYPEREOSINOPHILIC SYNDROME, VARIANTS GLY-481; PRO-507; MET-562;
RP   ARG-570; GLN-650; SER-659; PRO-705; GLY-748 AND SER-849,
RP   CHARACTERIZATION OF VARIANTS GLY-481; PRO-507; MET-562; ARG-570;
RP   GLN-650; SER-659; PRO-705; GLY-748 AND SER-849, AND ENZYME REGULATION.
RX   PubMed=21224473; DOI=10.1182/blood-2010-05-286757;
RA   Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M.,
RA   Stehling M., Serve H., Cross N.C., Hochhaus A., Hofmann W.K.,
RA   Berdel W.E., Muller-Tidow C., Reiter A., Koschmieder S.;
RT   "Novel imatinib-sensitive PDGFRA-activating point mutations in
RT   hypereosinophilic syndrome induce growth factor independence and
RT   leukemia-like disease.";
RL   Blood 117:2935-2943(2011).
RN   [33]
RP   FUNCTION IN CELL DIFFERENTIATION, AND UBIQUITINATION.
RX   PubMed=21596750; DOI=10.1074/jbc.M110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by
RT   decreased Cbl-mediated platelet-derived growth factor receptor alpha
RT   and fibroblast growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [34]
RP   ROLE IN DISEASE, CHARACTERIZATION OF VARIANT VAL-842, AND ENZYME
RP   REGULATION.
RX   PubMed=20972453; DOI=10.1038/onc.2010.476;
RA   von Bubnoff N., Gorantla S.P., Engh R.A., Oliveira T.M., Thone S.,
RA   Aberg E., Peschel C., Duyster J.;
RT   "The low frequency of clinical resistance to PDGFR inhibitors in
RT   myeloid neoplasms with abnormalities of PDGFRA might be related to the
RT   limited repertoire of possible PDGFRA kinase domain mutations in
RT   vitro.";
RL   Oncogene 30:933-943(2011).
RN   [35]
RP   REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION.
RX   PubMed=9739761; DOI=10.1016/S0304-419X(98)00015-8;
RA   Heldin C.H., Ostman A., Ronnstrand L.;
RT   "Signal transduction via platelet-derived growth factor receptors.";
RL   Biochim. Biophys. Acta 1378:F79-113(1998).
RN   [36]
RP   REVIEW ON ROLE IN DISEASE AND ENZYME REGULATION.
RX   PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002;
RA   Ostman A.;
RT   "PDGF receptors-mediators of autocrine tumor growth and regulators of
RT   tumor vasculature and stroma.";
RL   Cytokine Growth Factor Rev. 15:275-286(2004).
RN   [37]
RP   REVIEW ON ROLE IN DISEASE AND ENZYME REGULATION.
RX   PubMed=17419949; DOI=10.1016/S0065-230X(06)97011-0;
RA   Ostman A., Heldin C.H.;
RT   "PDGF receptors as targets in tumor treatment.";
RL   Adv. Cancer Res. 97:247-274(2007).
RN   [38]
RP   REVIEW ON FUNCTION IN DEVELOPMENT AND DISEASE; LIGANDS AND SIGNALING
RP   PATHWAYS.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1185-1189 IN COMPLEX WITH
RP   SLC9A3R1 AND PDGFRB.
RX   PubMed=11882663; DOI=10.1074/jbc.M201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-79; ASP-426; PRO-478; CYS-764;
RP   ARG-829; LYS-996 AND ASN-1071.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for PDGFA, PDGFB and PDGFC and plays an essential role in
CC       the regulation of embryonic development, cell proliferation,
CC       survival and chemotaxis. Depending on the context, promotes or
CC       inhibits cell proliferation and cell migration. Plays an important
CC       role in the differentiation of bone marrow-derived mesenchymal
CC       stem cells. Required for normal skeleton development and cephalic
CC       closure during embryonic development. Required for normal
CC       development of the mucosa lining the gastrointestinal tract, and
CC       for recruitment of mesenchymal cells and normal development of
CC       intestinal villi. Plays a role in cell migration and chemotaxis in
CC       wound healing. Plays a role in platelet activation, secretion of
CC       agonists from platelet granules, and in thrombin-induced platelet
CC       aggregation. Binding of its cognate ligands - homodimeric PDGFA,
CC       homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFC -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand
CC       and is modulated by the formation of heterodimers between PDGFRA
CC       and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation
CC       of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate,
CC       mobilization of cytosolic Ca(2+) and the activation of protein
CC       kinase C. Phosphorylates PIK3R1, the regulatory subunit of
CC       phosphatidylinositol 3-kinase, and thereby mediates activation of
CC       the AKT1 signaling pathway. Mediates activation of HRAS and of the
CC       MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of
CC       STAT family members STAT1, STAT3 and STAT5A and/or STAT5B.
CC       Receptor signaling is down-regulated by protein phosphatases that
CC       dephosphorylate the receptor and its down-stream effectors, and by
CC       rapid internalization of the activated receptor.
CC       {ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:10947961,
CC       ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:12522257,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:1709159,
CC       ECO:0000269|PubMed:17141222, ECO:0000269|PubMed:20972453,
CC       ECO:0000269|PubMed:21224473, ECO:0000269|PubMed:21596750,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664,
CC       ECO:0000269|PubMed:8760137, ECO:0000269|PubMed:8943348}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of PDGFA and/or PDGFB leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib, nilotinib and sorafenib.
CC       {ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453,
CC       ECO:0000269|PubMed:21224473}.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFA, PDGFB and PDGFC, and
CC       with heterodimers formed by PDGFA and PDGFB. Monomer in the
CC       absence of bound ligand. Interaction with dimeric PDGFA, PDGFB
CC       and/or PDGFC leads to receptor dimerization, where both PDGFRA
CC       homodimers and heterodimers with PDGFRB are observed. Interacts
CC       (tyrosine phosphorylated) with SHB (via SH2 domain) (By
CC       similarity). Interacts (tyrosine phosphorylated) with SHF (via SH2
CC       domain). Interacts (tyrosine phosphorylated) with SRC (via SH2
CC       domain). Interacts (tyrosine phosphorylated) with PIK3R1.
CC       Interacts (tyrosine phosphorylated) with PLCG1 (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CRK, GRB2 and GRB7.
CC       Interacts with human cytomegalovirus/HHV-5 envelop glycoprotein
CC       B/gB. {ECO:0000250, ECO:0000269|PubMed:10733900,
CC       ECO:0000269|PubMed:11095946, ECO:0000269|PubMed:11297552,
CC       ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:1709159,
CC       ECO:0000269|PubMed:20660204, ECO:0000269|PubMed:2173144,
CC       ECO:0000269|PubMed:2536956, ECO:0000269|PubMed:2544881,
CC       ECO:0000269|PubMed:7535778, ECO:0000269|PubMed:7679113,
CC       ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:8943348}.
CC   -!- INTERACTION:
CC       Q8N6L0:CCDC155; NbExp=3; IntAct=EBI-2861522, EBI-749265;
CC       P46108:CRK; NbExp=4; IntAct=EBI-2861522, EBI-886;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-2861522, EBI-910;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-2861522, EBI-297353;
CC       P04085:PDGFA; NbExp=6; IntAct=EBI-2861522, EBI-2881386;
CC       P01127:PDGFB; NbExp=11; IntAct=EBI-2861522, EBI-1554925;
CC       Q9NRA1:PDGFC; NbExp=2; IntAct=EBI-2861522, EBI-8833587;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664}. Note=The
CC       activated receptor is rapidly internalized and degraded.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P16234-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16234-2; Sequence=VSP_007833, VSP_007834;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P16234-3; Sequence=VSP_042015, VSP_042016;
CC   -!- TISSUE SPECIFICITY: Detected in platelets (at protein level).
CC       Widely expressed. Detected in brain, fibroblasts, smooth muscle,
CC       heart, and embryo. Expressed in primary and metastatic colon
CC       tumors and in normal colon tissue. {ECO:0000269|PubMed:2536956,
CC       ECO:0000269|PubMed:7896447, ECO:0000269|PubMed:8188664}.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: Ubiquitinated, leading to its degradation.
CC       {ECO:0000305|PubMed:21596750}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-731 and Tyr-742 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-720 and Tyr-754 is
CC       important for interaction with PTPN11. Phosphorylation at Tyr-762
CC       is important for interaction with CRK. Phosphorylation at Tyr-572
CC       and Tyr-574 is important for interaction with SRC and SRC family
CC       members. Phosphorylation at Tyr-988 and Tyr-1018 is important for
CC       interaction with PLCG1. {ECO:0000269|PubMed:10733900,
CC       ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:11095946,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:7535778,
CC       ECO:0000269|PubMed:8943348}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRA is found
CC       in some cases of hypereosinophilic syndrome. Interstitial
CC       chromosomal deletion del(4)(q12q12) causes the fusion of FIP1L1
CC       and PDGFRA (FIP1L1-PDGFRA). Mutations that cause overexpression
CC       and/or constitutive activation of PDGFRA may be a cause of
CC       hypereosinophilic syndrome. {ECO:0000269|PubMed:12808148}.
CC   -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]:
CC       Common mesenchymal neoplasms arising in the gastrointestinal
CC       tract, most often in the stomach. They are histologically,
CC       immunohistochemically, and genetically different from typical
CC       leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are
CC       composed of a fairly uniform population of spindle-shaped cells.
CC       Some tumors are dominated by epithelioid cells or contain a
CC       mixture of spindle and epithelioid morphologies. Primary GISTs in
CC       the gastrointestinal tract commonly metastasize in the omentum and
CC       mesenteries, often as multiple nodules. However, primary tumors
CC       may also occur outside of the gastrointestinal tract, in other
CC       intra-abdominal locations, especially in the omentum and
CC       mesentery. {ECO:0000269|PubMed:12522257,
CC       ECO:0000269|PubMed:15928335}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis. Mutations causing
CC       PDGFRA constitutive activation have been found in gastrointestinal
CC       stromal tumors lacking KIT mutations (PubMed:12522257).
CC       {ECO:0000269|PubMed:12522257}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP69563.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22734; AAA60048.1; -; mRNA.
DR   EMBL; M21574; AAA96715.1; -; mRNA.
DR   EMBL; D50017; BAA08742.1; -; Genomic_DNA.
DR   EMBL; AK316578; BAG38166.1; -; mRNA.
DR   EMBL; AC098587; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC138779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015186; AAH15186.1; -; mRNA.
DR   EMBL; BC063414; AAH63414.1; -; mRNA.
DR   EMBL; AY229892; AAP69563.1; ALT_INIT; mRNA.
DR   CCDS; CCDS3495.1; -. [P16234-1]
DR   PIR; A40162; PFHUGA.
DR   RefSeq; NP_001334758.1; NM_001347829.1. [P16234-1]
DR   RefSeq; NP_006197.1; NM_006206.5. [P16234-1]
DR   RefSeq; XP_005265800.1; XM_005265743.1. [P16234-1]
DR   UniGene; Hs.74615; -.
DR   PDB; 1GQ5; X-ray; 2.20 A; -.
DR   PDB; 5K5X; X-ray; 2.17 A; A=550-973.
DR   PDBsum; 1GQ5; -.
DR   PDBsum; 5K5X; -.
DR   ProteinModelPortal; P16234; -.
DR   SMR; P16234; -.
DR   BioGrid; 111182; 53.
DR   DIP; DIP-5736N; -.
DR   IntAct; P16234; 38.
DR   MINT; MINT-4529366; -.
DR   STRING; 9606.ENSP00000257290; -.
DR   BindingDB; P16234; -.
DR   ChEMBL; CHEMBL2007; -.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB05216; MP470.
DR   DrugBank; DB06043; Olaratumab.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05146; XL820.
DR   GuidetoPHARMACOLOGY; 1803; -.
DR   iPTMnet; P16234; -.
DR   PhosphoSitePlus; P16234; -.
DR   BioMuta; PDGFRA; -.
DR   DMDM; 129892; -.
DR   MaxQB; P16234; -.
DR   PaxDb; P16234; -.
DR   PeptideAtlas; P16234; -.
DR   PRIDE; P16234; -.
DR   DNASU; 5156; -.
DR   Ensembl; ENST00000257290; ENSP00000257290; ENSG00000134853. [P16234-1]
DR   Ensembl; ENST00000508170; ENSP00000425648; ENSG00000134853. [P16234-2]
DR   Ensembl; ENST00000509490; ENSP00000424218; ENSG00000134853. [P16234-3]
DR   GeneID; 5156; -.
DR   KEGG; hsa:5156; -.
DR   UCSC; uc003hal.4; human. [P16234-1]
DR   CTD; 5156; -.
DR   DisGeNET; 5156; -.
DR   GeneCards; PDGFRA; -.
DR   HGNC; HGNC:8803; PDGFRA.
DR   HPA; CAB018143; -.
DR   HPA; HPA004947; -.
DR   MalaCards; PDGFRA; -.
DR   MIM; 173490; gene.
DR   MIM; 606764; phenotype.
DR   MIM; 607685; phenotype.
DR   neXtProt; NX_P16234; -.
DR   OpenTargets; ENSG00000134853; -.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 168947; Myeloid neoplasm associated with PDGFRA rearrangement.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   PharmGKB; PA33147; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112009; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P16234; -.
DR   KO; K04363; -.
DR   OMA; DSAIIPC; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P16234; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   SignaLink; P16234; -.
DR   SIGNOR; P16234; -.
DR   ChiTaRS; PDGFRA; human.
DR   EvolutionaryTrace; P16234; -.
DR   GeneWiki; PDGFRA; -.
DR   GenomeRNAi; 5156; -.
DR   PRO; PR:P16234; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000134853; -.
DR   CleanEx; HS_PDGFRA; -.
DR   ExpressionAtlas; P16234; baseline and differential.
DR   Genevisible; P16234; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0005018; F:platelet-derived growth factor alpha-receptor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB.
DR   GO; GO:0001775; P:cell activation; TAS:BHF-UCL.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001553; P:luteinization; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:UniProtKB.
DR   GO; GO:2000587; P:negative regulation of platelet-derived growth factor receptor-beta signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035790; P:platelet-derived growth factor receptor-alpha signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0050920; P:regulation of chemotaxis; IMP:UniProtKB.
DR   GO; GO:2000739; P:regulation of mesenchymal stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 6.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027290; PDGFRA.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500950; Alpha-PDGF_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chemotaxis; Complete proteome; Developmental protein; Disulfide bond;
KW   Glycoprotein; Host-virus interaction; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     23
FT   CHAIN        24   1089       Platelet-derived growth factor receptor
FT                                alpha.
FT                                /FTId=PRO_0000016760.
FT   TOPO_DOM     24    528       Extracellular. {ECO:0000255}.
FT   TRANSMEM    529    549       Helical. {ECO:0000255}.
FT   TOPO_DOM    550   1089       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24    113       Ig-like C2-type 1.
FT   DOMAIN      117    201       Ig-like C2-type 2.
FT   DOMAIN      202    306       Ig-like C2-type 3.
FT   DOMAIN      319    410       Ig-like C2-type 4.
FT   DOMAIN      414    517       Ig-like C2-type 5.
FT   DOMAIN      593    954       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     599    607       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS   1041   1087       Ser-rich.
FT   ACT_SITE    818    818       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     627    627       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        578    579       Breakpoint for interstitial deletion to
FT                                form the FIP1L1-PDGFRA fusion protein.
FT   MOD_RES     572    572       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10734113}.
FT   MOD_RES     574    574       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10734113}.
FT   MOD_RES     720    720       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11095946,
FT                                ECO:0000269|PubMed:8943348}.
FT   MOD_RES     731    731       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1646396}.
FT   MOD_RES     742    742       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1646396}.
FT   MOD_RES     754    754       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17604334}.
FT   MOD_RES     762    762       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10733900}.
FT   MOD_RES     768    768       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8617789}.
FT   MOD_RES     849    849       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     988    988       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7535778}.
FT   MOD_RES    1018   1018       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7535778}.
FT   CARBOHYD     42     42       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     76     76       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    179    179       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    359    359       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    458    458       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     49    100       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    150    189       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    235    290       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    435    501       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     210    218       ATSELDLEM -> GTCIISFLL (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007833.
FT   VAR_SEQ     219   1089       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007834.
FT   VAR_SEQ     720    743       YVILSFENNGDYMDMKQADTTQYV -> SGQGCLSSGTLQE
FT                                LSVDLQARGPC (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042015.
FT   VAR_SEQ     744   1089       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042016.
FT   VARIANT      79     79       G -> D (in dbSNP:rs36035373).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042032.
FT   VARIANT     426    426       G -> D (in dbSNP:rs55865821).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042033.
FT   VARIANT     478    478       S -> P (in dbSNP:rs35597368).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034378.
FT   VARIANT     481    481       R -> G (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066460.
FT   VARIANT     507    507       L -> P (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066461.
FT   VARIANT     561    561       V -> D (in a GIST sample; constitutively
FT                                activated kinase; dbSNP:rs121908586).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066462.
FT   VARIANT     562    562       I -> M (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066463.
FT   VARIANT     570    570       H -> R (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066464.
FT   VARIANT     650    650       H -> Q (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066465.
FT   VARIANT     659    659       N -> K (in GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066466.
FT   VARIANT     659    659       N -> S (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066467.
FT   VARIANT     705    705       L -> P (in a hypereosinophilic syndrome
FT                                sample; does not lead to constitutive
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066468.
FT   VARIANT     748    748       R -> G (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066469.
FT   VARIANT     764    764       R -> C (in dbSNP:rs34392012).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042034.
FT   VARIANT     829    829       G -> R (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042035.
FT   VARIANT     842    845       Missing (in a GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066470.
FT   VARIANT     842    842       D -> V (in a GIST sample; imatinib
FT                                resistant, constitutively activated
FT                                kinase; dbSNP:rs121908585).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335,
FT                                ECO:0000269|PubMed:20972453}.
FT                                /FTId=VAR_066471.
FT   VARIANT     842    842       D -> Y (in a GIST sample; imatinib
FT                                sensitive, constitutively activated
FT                                kinase; dbSNP:rs121913265).
FT                                {ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066472.
FT   VARIANT     845    848       Missing (in a GIST sample; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:12522257,
FT                                ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066473.
FT   VARIANT     849    849       Y -> C (in GIST).
FT                                {ECO:0000269|PubMed:15928335}.
FT                                /FTId=VAR_066474.
FT   VARIANT     849    849       Y -> S (in a hypereosinophilic syndrome
FT                                sample; constitutively activated kinase).
FT                                {ECO:0000269|PubMed:21224473}.
FT                                /FTId=VAR_066475.
FT   VARIANT     996    996       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation; dbSNP:rs779173667).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042036.
FT   VARIANT    1071   1071       D -> N (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation;
FT                                dbSNP:rs376544204).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042037.
FT   MUTAGEN     572    572       Y->F: Abolishes interaction with SRC-
FT                                family members and impairs
FT                                internalization of the activated
FT                                receptor; when associated with F-574.
FT                                {ECO:0000269|PubMed:10734113,
FT                                ECO:0000269|PubMed:14644164}.
FT   MUTAGEN     574    574       Y->F: Abolishes interaction with SRC-
FT                                family members and impairs
FT                                internalization of the activated
FT                                receptor; when associated with F-572.
FT                                {ECO:0000269|PubMed:10734113,
FT                                ECO:0000269|PubMed:14644164}.
FT   MUTAGEN     720    720       Y->F: Strongly reduced interaction with
FT                                PTPN11 and GRB2.
FT                                {ECO:0000269|PubMed:8943348}.
FT   MUTAGEN     731    731       Y->F: No effect on autophosphorylation
FT                                and phosphorylation of PLCG1. Abolishes
FT                                activation of phosphatidylinositol 3-
FT                                kinase. {ECO:0000269|PubMed:1646396}.
FT   MUTAGEN     742    742       Y->F: No effect on autophosphorylation
FT                                and phosphorylation of PLCG1. Abolishes
FT                                activation of phosphatidylinositol 3-
FT                                kinase. {ECO:0000269|PubMed:1646396}.
FT   MUTAGEN     762    762       Y->F: Abolishes interaction with CRK.
FT                                {ECO:0000269|PubMed:10733900}.
FT   STRAND      560    565       {ECO:0000244|PDB:5K5X}.
FT   STRAND      572    574       {ECO:0000244|PDB:5K5X}.
FT   HELIX       577    579       {ECO:0000244|PDB:5K5X}.
FT   HELIX       584    586       {ECO:0000244|PDB:5K5X}.
FT   HELIX       590    592       {ECO:0000244|PDB:5K5X}.
FT   STRAND      593    601       {ECO:0000244|PDB:5K5X}.
FT   STRAND      603    615       {ECO:0000244|PDB:5K5X}.
FT   STRAND      620    629       {ECO:0000244|PDB:5K5X}.
FT   HELIX       635    651       {ECO:0000244|PDB:5K5X}.
FT   STRAND      660    664       {ECO:0000244|PDB:5K5X}.
FT   STRAND      666    669       {ECO:0000244|PDB:5K5X}.
FT   STRAND      671    675       {ECO:0000244|PDB:5K5X}.
FT   HELIX       682    688       {ECO:0000244|PDB:5K5X}.
FT   HELIX       774    776       {ECO:0000244|PDB:5K5X}.
FT   HELIX       778    781       {ECO:0000244|PDB:5K5X}.
FT   HELIX       792    811       {ECO:0000244|PDB:5K5X}.
FT   HELIX       821    823       {ECO:0000244|PDB:5K5X}.
FT   STRAND      824    827       {ECO:0000244|PDB:5K5X}.
FT   TURN        828    830       {ECO:0000244|PDB:5K5X}.
FT   STRAND      831    834       {ECO:0000244|PDB:5K5X}.
FT   HELIX       838    840       {ECO:0000244|PDB:5K5X}.
FT   HELIX       843    845       {ECO:0000244|PDB:5K5X}.
FT   STRAND      850    852       {ECO:0000244|PDB:5K5X}.
FT   STRAND      855    857       {ECO:0000244|PDB:5K5X}.
FT   HELIX       859    861       {ECO:0000244|PDB:5K5X}.
FT   HELIX       864    869       {ECO:0000244|PDB:5K5X}.
FT   HELIX       874    889       {ECO:0000244|PDB:5K5X}.
FT   HELIX       903    910       {ECO:0000244|PDB:5K5X}.
FT   HELIX       923    932       {ECO:0000244|PDB:5K5X}.
FT   HELIX       937    939       {ECO:0000244|PDB:5K5X}.
FT   HELIX       943    951       {ECO:0000244|PDB:5K5X}.
FT   HELIX       956    971       {ECO:0000244|PDB:5K5X}.
SQ   SEQUENCE   1089 AA;  122670 MW;  5E3FB9940ACD1BE8 CRC64;
     MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP
     MSEEESSDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY
     VPDPDVAFVP LGMTDYLVIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNG
     TFTVGPYICE ATVKGKKFQT IPFNVYALKA TSELDLEMEA LKTVYKSGET IVVTCAVFNN
     EVVDLQWTYP GEVKGKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK
     EMKKVTISVH EKGFIEIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL KNNLTLIENL
     TEITTDVEKI QEIRYRSKLK LIRAKEEDSG HYTIVAQNED AVKSYTFELL TQVPSSILDL
     VDDHHGSTGG QTVRCTAEGT PLPDIEWMIC KDIKKCNNET SWTILANNVS NIITEIHSRD
     RSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSELTVAAA VLVLLVIVII
     SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRVLG
     SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
     LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK PKKELDIFGL NPADESTRSY
     VILSFENNGD YMDMKQADTT QYVPMLERKE VSKYSDIQRS LYDRPASYKK KSMLDSEVKN
     LLSDDNSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA
     RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
     VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
     SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
     PLPDIDPVPE EEDLGKRNRH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
     SDLVEDSFL
//
